| Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy SJ Howard, JM Lestner, A Sharp, L Gregson, J Goodwin, J Slater, ... Journal of Infectious Diseases 203 (9), 1324-1332, 2011 | 117 | 2011 |
| In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. PA Warn, A Sharp, DW Denning Journal of Antimicrobial Chemotherapy 57 (1), 135-138, 2006 | 107 | 2006 |
| Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal … PA Warn, A Sharp, A Parmar, J Majithiya, DW Denning, WW Hope Antimicrobial agents and chemotherapy 53 (8), 3453-3461, 2009 | 97 | 2009 |
| Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa TW Felton, J Goodwin, L O'Connor, A Sharp, L Gregson, J Livermore, ... Antimicrobial agents and chemotherapy 57 (12), 5811-5819, 2013 | 93 | 2013 |
| Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections PA Warn, MW Brampton, A Sharp, G Morrissey, N Steel, DW Denning, ... Laboratory Animals 37 (2), 126-131, 2003 | 90 | 2003 |
| In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Mosquera, A Sharp, CB Moore, PA Warn, DW Denning Journal of Antimicrobial Chemotherapy 50 (2), 189-194, 2002 | 90 | 2002 |
| Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus PA Warn, A Sharp, J Mosquera, J Spickermann, A Schmitt-Hoffmann, ... Journal of antimicrobial chemotherapy 58 (6), 1198-1207, 2006 | 86 | 2006 |
| Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™ JL Italia, A Sharp, KC Carter, P Warn, MNVR Kumar PloS one 6 (10), e25744, 2011 | 74 | 2011 |
| Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei J Majithiya, A Sharp, A Parmar, DW Denning, PA Warn Journal of Antimicrobial Chemotherapy 63 (1), 161-166, 2009 | 72 | 2009 |
| Infection augments expression of mechanosensing Piezo1 channels in amyloid plaque-reactive astrocytes M Velasco-Estevez, M Mampay, H Boutin, A Chaney, P Warn, A Sharp, ... Frontiers in aging neuroscience 10, 332, 2018 | 69 | 2018 |
| Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility … A Sudan, J Livermore, SJ Howard, Z Al-Nakeeb, A Sharp, J Goodwin, ... Antimicrobial agents and chemotherapy 57 (6), 2793-2800, 2013 | 69 | 2013 |
| The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection M Alsaadi, JL Italia, AB Mullen, MNVR Kumar, AA Candlish, ... Journal of controlled release 160 (3), 685-691, 2012 | 66 | 2012 |
| Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis WW Hope, GL Drusano, CB Moore, A Sharp, A Louie, TJ Walsh, ... Antimicrobial agents and chemotherapy 51 (1), 285-295, 2007 | 62 | 2007 |
| Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis WW Hope, GL Drusano, CB Moore, A Sharp, A Louie, TJ Walsh, ... Antimicrobial agents and chemotherapy 51 (1), 285-295, 2007 | 62 | 2007 |
| Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα Á Dénes, JM Pradillo, C Drake, A Sharp, P Warn, KN Murray, B Rohit, ... Annals of neurology 75 (5), 670-683, 2014 | 60 | 2014 |
| Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients L O'Connor, J Livermore, AD Sharp, J Goodwin, L Gregson, SJ Howard, ... The Journal of infectious diseases 208 (2), 351-361, 2013 | 58 | 2013 |
| Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin JL Slater, SJ Howard, A Sharp, J Goodwin, LM Gregson, ... Antimicrobial agents and chemotherapy 55 (7), 3075-3083, 2011 | 58 | 2011 |
| Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the … WW Hope, PA Warn, A Sharp, S Howard, M Kasai, A Louie, TJ Walsh, ... Antimicrobial agents and chemotherapy 50 (11), 3680-3688, 2006 | 50 | 2006 |
| Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida PA Warn, A Sharp, J Guinea, DW Denning Journal of Antimicrobial Chemotherapy 53 (5), 743-749, 2004 | 50 | 2004 |
| Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts SJ Howard, J Livermore, A Sharp, J Goodwin, L Gregson, ... Antimicrobial agents and chemotherapy 55 (10), 4880-4887, 2011 | 47 | 2011 |
S J HowardVerified email at virginmedia.com
